Codexis Achieves Development Milestone in Partnership with Schering-Plough

Codexis, Inc. has reached an important development milestone under a research agreement with Schering-Plough Corporation (SGP). The collaboration aims to rapidly generate a novel biocatalytic process for producing a key intermediate in an undisclosed human therapeutics compound. This project leverages Codexis' proprietary MolecularBreeding platform, which is expected to reduce manufacturing costs and environmental waste in the production process. The agreement was announced in March, and Codexis has quickly met the initial development milestone, with the company's president and CEO, Alan Shaw, expressing satisfaction with the progress made.

Key Takeaways:

• Codexis has achieved a development milestone under a research agreement with Schering-Plough Corporation (SGP) to generate a novel biocatalytic process for a key intermediate in an undisclosed human therapeutics compound.
• The collaboration uses Codexis' proprietary MolecularBreeding platform, which is expected to reduce manufacturing costs and environmental waste in the production process.
• Codexis has a track record of applying its technology to improve purity profile and reduce manufacturing time, cost, and waste for high-value pharmaceutical products.
• The company has more than 15 partnerships with worldwide proprietary and generic pharmaceutical manufacturers.
• Codexis' platform technology can reduce cost of goods by 40 to 70% and capital expenditures by over 35%.
• The technology creates new intellectual property opportunities, extending the lifetime of drug products.
• Codexis' platform technology begins with the selection of genes or genomes with DNA sequence diversity, then recombines and screens for novel biocatalysts with desirable properties.
• The company's partnerships draw upon its expertise in developing rapid, efficient clinical-scale manufacturing production processes.

Statistics:

• Codexis' platform technology can reduce cost of goods by 40 to 70%.
• The technology also reduces capital expenditures by over 35%.
• Codexis has established more than 15 partnerships with worldwide proprietary and generic pharmaceutical manufacturers.
• The company's platform technology is used to improve purity profile and reduce manufacturing time, cost, and waste for high-value pharmaceutical products.
• The average reduction in manufacturing costs and environmental waste is expected to be significant, although a specific percentage is not provided.

Sources:

• Codexis, Inc. press release
• Health & Medicine Week
• NewsRx.com

("Codexis, Inc. ; confirms agreement with Schering-Plough

via Health & Medicine Week")

Copyright 2006, Health & Medicine Week via NewsRx.com